Patents by Inventor Kwang-Hoe Chung
Kwang-Hoe Chung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10494343Abstract: The present invention relates to a novel organic compound, a near-infrared fluorescent constant medium containing the same, and a method for nano-granulating the constant medium.Type: GrantFiled: January 11, 2016Date of Patent: December 3, 2019Assignees: COLLEGE OF MEDICINE POCHON CHA UNIV. INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHAMEDITECH CO., LTD.Inventors: Tae Jong Yoon, Kwang Hoe Chung, Jeongbeob Seo, Sin Wook Kang, Kwang Hyuong Lee, Yong Su Kwon, Hye Sun Jeon, Chae Woon Lee, Jin Sung Kim
-
Publication number: 20180327357Abstract: The present invention relates to a novel organic compound, a near-infrared fluorescent constant medium containing the same, and a method for nano-granulating the constant medium.Type: ApplicationFiled: January 11, 2016Publication date: November 15, 2018Inventors: Tae Jong Yoon, Kwang Hoe Chung, Jeongbeob Seo, Sin Wook Kang, Kwang Hyuong Lee, Yong Su Kwon, Hye Sun Jeon, Chae Woon Lee, Jin sung Kim
-
Patent number: 9897616Abstract: Disclosed are a monoclonal antibody against human D-dimer produced in a mouse and high molecular weight cross-linked fibrin including a corresponding epitope, a cell line secreting the monoclonal antibody, and methods for producing the same. The anti-D-dimer monoclonal antibody of the present invention may be effectively used as a diagnosis agent for screening and detecting in-vivo D-dimer, and high molecular weight cross-linked fibrin and its derivatives containing the D-dimer since the monoclonal antibody specifically reacts with D-dimer, and cross-linked fibrin and its derivatives containing the D-dimer, which do not bind to human fibrinogen or fibrin.Type: GrantFiled: December 23, 2014Date of Patent: February 20, 2018Inventors: Hyun-Ju Doh, Doo-Sik Kim, Kwang-Hoe Chung
-
Publication number: 20150177265Abstract: Disclosed are a monoclonal antibody against human D-dimer produced in a mouse and high molecular weight cross-linked fibrin including a corresponding epitope, a cell line secreting the monoclonal antibody, and methods for producing the same. The anti-D-dimer monoclonal antibody of the present invention may be effectively used as a diagnosis agent for screening and detecting in-vivo D-dimer, and high molecular weight cross-linked fibrin and its derivatives containing the D-dimer since the monoclonal antibody specifically reacts with D-dimer, and cross-linked fibrin and its derivatives containing the D-dimer, which do not bind to human fibrinogen or fibrin.Type: ApplicationFiled: December 23, 2014Publication date: June 25, 2015Applicant: PRINCETON BIOMEDITECH CORPORATIONInventors: Hyun-Ju Doh, Doo-Sik Kim, Kwang-Hoe Chung
-
Patent number: 8940489Abstract: Disclosed are a monoclonal antibody against human D-dimer produced in a mouse and high molecular weight cross-linked fibrin including a corresponding epitope, a cell line secreting the monoclonal antibody, and methods for producing the same. The anti-D-dimer monoclonal antibody of the present invention may be effectively used as a diagnotic agent for screening and detecting in-vivo D-dimer, and high molecular weight cross-linked fibrin and its derivatives containing the D-dimer since the monoclonal antibody specifically reacts with D-dimer, and cross-linked fibrin and its derivatives containing the D-dimer, which do not bind to human fibrinogen or fibrin.Type: GrantFiled: April 22, 2009Date of Patent: January 27, 2015Inventors: Hyun-Ju Doh, Doo-Sik Kim, Kwang-Hoe Chung
-
Patent number: 8475633Abstract: Provided is a method for preparing an epoxy substrate having a nanopattern, including: (a) forming a titanium oxide film by anodizing a titanium substrate; (b) obtaining a titanium substrate having a concave shape formed on the surface by removing the titanium oxide film from the titanium substrate on which the titanium oxide film has been formed; (c) coating an epoxy resin onto the titanium substrate on which the concave shape has been formed; and (d) obtaining an epoxy substrate having a nanopattern of convex surfaces by removing the titanium substrate.Type: GrantFiled: April 14, 2009Date of Patent: July 2, 2013Assignee: BioBud Co., Ltd.Inventors: Kwang Hoe Chung, Sung Yu Hong, Hyun Ju Doh, Jin Sub Choi, Jae Hoon Lim, Sung Joong Kim
-
Patent number: 8377676Abstract: The present invention relates to a batroxobin-encoding nucleotide sequence and/or a mutated ?-factor secretion signal sequence, and a vector and a transformant using the same. The batroxobin-encoding nucleotide sequence of this invention exhibits an excellent expression efficiency in yeast, particular Pichia pastoris and the recombinant batroxobin is obtained at 4-13 fold higher yield than natural-occurring batroxobin-encoding sequences. The protein expression system which uses the batroxobin-encoding nucleotide sequence as well as mutated ?-factor secretion signal peptide sequence of this invention obtains the recombinant batroxobin at about 20-fold higher yield than natural-occurring batroxobin-encoding sequences. In addition, the recombinant batroxobin prepared using the sequence of this invention has a significantly plausible activity and stability compared with natural-occurring batroxobin.Type: GrantFiled: December 23, 2008Date of Patent: February 19, 2013Assignee: Biobud Co., LtdInventors: Young-Doug Sohn, Bum Joon Kim, Ok Hwan Kim, Kyoung Jun Kim, Ji Hun Shin, Sung Yu Hong, Jae Hoon Hwang, Kwang Hoe Chung
-
Patent number: 8106071Abstract: The present invention relates to a method for treating or reducing the development of a hyperproliferative disorder, which comprises administering to a subject a composition, which comprises as an active ingredient the compound represented by the Formula 1: wherein R1, R2, R3, R4, R5, R6 and R7 independently represent hydrogen, halo, hydroxyl, cyano, amino, nitro, nitroso, carboxyl, C1-C12 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, C1-C6 alkylamino, C1-C6 alkoxy, aryl, heteroaryl, arylalkyl, arylalkenyl or alkylaryl; X and Y independently represent hydrogen, oxygen, or sulfur, bound to a carbon atom via a single or double bond; Z represents hydrogen, halo, hydroxyl, cyano, amino, nitro, nitroso, carboxyl, C1-C12 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, C1-C6 alkylamino, C1-C6 alkoxy, aryl, heteroaryl, arylalkyl, arylalkenyl, alkylaryl or —NH—R8; R8 represents hydrogen, halo, hydroxyl, cyano, amino, nitro, nitroso, carboxyl, C1-C12 alkyl, C2-C6 alkenyl, C3-C8 cyType: GrantFiled: May 23, 2007Date of Patent: January 31, 2012Assignee: Biobud Co., Ltd.Inventors: Kwang Hoe Chung, Chwang Siek Pak, Sung Yu Hong, Soo Jung Kang, Young Doug Sohn, Jae Hoon Hwang, Eun Bok Choi, Gyu Hwan Yon, Hyeon Kyu Lee, Heui Cheol Yang
-
Publication number: 20110155591Abstract: Provided is a method for preparing an epoxy substrate having a nanopattern, including: (a) forming a titanium oxide film by anodizing a titanium substrate; (b) obtaining a titanium substrate having a concave shape formed on the surface by removing the titanium oxide film from the titanium substrate on which the titanium oxide film has been formed; (c) coating an epoxy resin onto the titanium substrate on which the concave shape has been formed; and (d) obtaining an epoxy substrate having a nanopattern of convex surfaces by removing the titanium substrate. According to the presently disclosed method, an epoxy substrate having a nanopattern of convex surfaces is prepared by anodizing a titanium substrate, coating an epoxy resin onto a nanopattern formed with a concave shape on the surface of the titanium substrate, and removing the titanium substrate.Type: ApplicationFiled: April 14, 2009Publication date: June 30, 2011Inventors: Kwang Hoe Chung, Sung Yu Hong, Hyun Ju Doh, Jin Sub Choi, Jae Hoon Lim, Sung Joong Kim
-
Publication number: 20110136207Abstract: The present invention relates to a batroxobin-encoding nucleotide sequence and/or a mutated ?-factor secretion signal sequence, and a vector and a transformant using the same. The batroxobin-encoding nucleotide sequence of this invention exhibits an excellent expression efficiency in yeast, particular Pichia pastoris and the recombinant batroxobin is obtained at 4-13 fold higher yield than natural-occurring batroxobin-encoding sequences. The protein expression system which uses the batroxobin-encoding nucleotide sequence as well as mutated ?-factor secretion signal peptide sequence of this invention obtains the recombinant batroxobin at about 20-fold higher yield than natural-occurring batroxobin-encoding sequences. In addition, the recombinant batroxobin prepared using the sequence of this invention has a significantly plausible activity and stability compared with natural-occurring batroxobin.Type: ApplicationFiled: December 23, 2008Publication date: June 9, 2011Applicant: Biobud Co., Ltd.Inventors: Young-Doug Sohn, Bum Joon Kim, Ok Hwan Kim, Kyoung Jun Kim, Ji Hun Shin, Sung Yu Hong, Jae Hoon Hwang, Kwang Hoe Chung
-
Publication number: 20100120849Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hyperproliferative vascular disorders, and a pharmaceutical anticancer composition comprising the compound represented by the Formula 1. The present compounds exhibit IC50 values of less than 0.16 ?M for vascular smooth muscle cells and cancer cells to effectively prevent proliferation of vascular smooth muscle cells and cancer cells, thereby ensuring prevention or treatment of hyperproliferative vascular disorders such as arteriosclerosis and restenosis, and cancers.Type: ApplicationFiled: May 23, 2007Publication date: May 13, 2010Applicant: Biobud Co., LtdInventors: Kwang Hoe Chung, Chwang Siek Pak, Sung Yu Hong, Soo Jung Kang, Young Doug Sohn, Jae Hoon Hwang, Eun Bok Choi, Gyu Hwan Yon, Hyeon Kyu Lee, Heui Cheol Yang
-
Publication number: 20090298100Abstract: Disclosed are a monoclonal antibody against human D-dimer produced in a mouse and high molecular weight crosslinked fibrin including a corresponding epitope, a cell line secreting the monoclonal antibody, and a method for manufacturing the same. The anti-D-dimer monoclonal antibody of the present invention may be effectively used as a diagnosis agent for screening and detecting in vivo D-dimer, and high molecular weight crosslinked fibrin and its derivatives containing the D-dimer since the monoclonal antibody specifically reacts with D-dimer, and crosslinked fibrin and its derivatives containing the D-dimer, which do not bind to human fibrinogen or fibrin.Type: ApplicationFiled: April 22, 2009Publication date: December 3, 2009Inventors: Hyun-Ju Doh, Doo-Sik Kim, Kwang-Hoe Chung
-
Publication number: 20060281147Abstract: A recombinant thrombin-like enzyme batroxobin expressed by yeast, a production method thereof, and use of the batroxobin as a hemostatic agent or antithrombotic agent is disclosed. In order to express recombinant thrombin-like enzyme, an expression vector is prepared by inserting cDNA encoding the enzyme, the transformed cell is prepared by introducing the expression vector into the cell, the transformed cell then is incubated and the recombinant thrombin-like enzyme is obtained from the cell. The recombinant thrombin-like enzyme may be usefully used as a hemostatic agent because the enzyme effectively decrease bleeding time and blood coagulation time and does not affect various blood coagulation factors.Type: ApplicationFiled: October 31, 2003Publication date: December 14, 2006Applicant: BIOBUD CO., LTD.Inventors: Weon Kyoo You, Won Seok Choi, You Seok Koh, Seung Woo Kang, Kwang Hoe Chung
-
Patent number: 7033788Abstract: The present invention relates to Saxatilin, a protein derived from the venom of a Korean snake, Agkistrodon saxatilis emelianov, a process for preparing Saxatilin, and pharmaceutical application of the same as anti-platelet aggregation agent and anti-tumor agent. The present inventors purified Saxatilin from the venom of Agkistrodon saxatilis emelianov, cloned its cDNA, and prepared recombinant Saxatilin by culturing a microorganism transformed with an expression vector containing the cDNA. Saxatilin effectively suppresses the platelet aggregation and angiogenesis of tumor cells, which makes possible its practical application as an active ingredient of anti-platelet agent and anti-tumor agent.Type: GrantFiled: March 26, 2002Date of Patent: April 25, 2006Inventors: Kwang-Hoe Chung, Doo-sik Kim, Sung-Yu Hong, You-Seok Koh, Young-Doug Sohn, Weon-Kyoo You, Yang-Soo Jang, Chin-Kyu Huh
-
Publication number: 20050032189Abstract: The present invention relates to Saxatilin, a protein derived from the venom of a Korean snake, Agkistrodon saxatilis emelianov, a process for preparing Saxatilin, and pharmaceutical application of the same as anti-platelet aggregation agent and anti-tumor agent. The present inventors purified Saxatilin from the venom of Agkistrodon saxatilis emelianov, cloned its cDNA, and prepared recombinant Saxatilin by culturing a microorganism transformed with an expression vector containing the cDNA. Saxatilin effectively suppresses the platelet aggregation and angiogenesis of tumor cells, which makes possible its practical application as an active ingredient of anti-platelet agent and anti-tumor agent.Type: ApplicationFiled: March 26, 2002Publication date: February 10, 2005Inventors: Kwang-Hoe Chung, Doo-Sik Kim, Sung-Yu Hong, You-Seok Koh, Young-Doug Sohn, Weon-Kyoo You, Yang-Soo Jang, Chin-Kyu Huh
-
Patent number: 6537551Abstract: The present invention relates to an anti-tumor agent comprising Salmosin which is a novel disintegrin containing Arg-Gly-Asp (RGD) sequence and derived from venom of Korean snake, Agkistrodon halys brevicaudus, as an active ingredient. Salmosin is a disintegrin which blocks the function of &agr;v&bgr;3 integrin and strongly inhibits tumor angiogenesis, tumor metastasis as well as growth of solid tumor. Salmosin does not exhibit cytotoxicity within an effective dose range where tumor growth is efficiently suppressed without any untoward effect on preexisting blood vessels and normal angiogenesis. Accordingly, Salmosin can be applied for the development of potent anti-tumor drugs which are effective for various types of cancers.Type: GrantFiled: February 2, 2001Date of Patent: March 25, 2003Inventors: Doo-Sik Kim, Kwang Hoe Chung, In-Cheol Kang
-
Publication number: 20010023242Abstract: The present invention relates to an anti-tumor agent comprising Salmosin which is a novel disintegrin containing Arg-Gly-Asp(RGD) sequence and derived from venom of Korean snake, Agkistrodon halys brevicaudus, as an active ingredient. Salmosin is a disintegrin which blocks the function of &agr;v&bgr;3 integrin and strongly inhibits tumor angiogenesis, tumor metastasis as well as growth of solid tumor. Salmosin does not exhibit cytotoxicity within an effective dose range where tumor growth is efficiently suppressed without any untoward effect on preexisting blood vessels and normal angiogenesis. Accordingly, Salmosin can be applied for the development of potent anti-tumor drugs which are effective for various types of cancers.Type: ApplicationFiled: February 1, 2001Publication date: September 20, 2001Applicant: Doo-Sik KIMInventors: Doo-Sik Kim, Kwang Hoe Chung, In-Cheol Kang
-
Patent number: 5889148Abstract: The present invention relates to novel antibiotic peptides which possess antibacterial and/or antifungal activities causing no cytotoxicity, and to antibacterial and/or antifungal agents containing said peptides as active ingredients. In accordance with the present invention, it has been discovered that a number of chemically-synthesized peptides which are derived from Tenecin, show superior antibacterial and/or antifungal activities, while causing no untoward effects, and they can be applied for the development of antibacterial and/or antifungal agents.Type: GrantFiled: August 27, 1996Date of Patent: March 30, 1999Assignee: Mogam Biotechnology Research InstituteInventors: Keun-Hyeung Lee, Sung-Yu Hong, Hyun-Sook Cho, Bok-Leul Lee, Kwang-Hoe Chung, Jeong-Hyeok Yoon, Jong-Eun Oh, Hong-Mo Moon
-
Patent number: 5821106Abstract: The present invention relates to a novel cDNA of direct-acting fibrinolytic serine protease ("Salmonase") which is prepared from a Korean viper, Salmosa(Agkistrodon halys brevicaudus), and a direct-acting fibrinolytic serine protease deduced therefrom. The cDNA of direct-acting fibrinolytic serine protease contains 699 nucleotides coding for 233 amino acids, and the Salmonase translated therefrom consists of two subunits of 77 and 156 amino acids, respectively. Salmonase cDNA of the invention may be expressed in the proper systems established in the recombinant E. coli, yeast, baculovirus/insect cells and other animal cells, and the recombinant Salmonase prepared therefrom can be practically applied as an active ingredient of thrombolytic and hemostatic agents.Type: GrantFiled: October 25, 1996Date of Patent: October 13, 1998Assignee: Mogam Biotechnology Research InstituteInventors: Kwang-Hoe Chung, You-Seok Koh, Jae-Hoon Hwang, Doo-Sik Kim, Yung-Dae Yun, Hong-Mo Moon